BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sharma N, Bhushan A, He J, Kaushal G, Bhardwaj V. Metabolic plasticity imparts erlotinib-resistance in pancreatic cancer by upregulating glucose-6-phosphate dehydrogenase. Cancer Metab 2020;8:19. [PMID: 32974013 DOI: 10.1186/s40170-020-00226-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Xu H, Chen R, Shen Q, Yang D, Peng H, Tong J, Fu Q. Overexpression of Circular RNA circ_0013587 Reverses Erlotinib Resistance in Pancreatic Cancer Cells Through Regulating the miR-1227/E-Cadherin Pathway. Front Oncol 2021;11:754146. [PMID: 34552882 DOI: 10.3389/fonc.2021.754146] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Tuerhong A, Xu J, Shi S, Tan Z, Meng Q, Hua J, Liu J, Zhang B, Wang W, Yu X, Liang C. Overcoming chemoresistance by targeting reprogrammed metabolism: the Achilles' heel of pancreatic ductal adenocarcinoma. Cell Mol Life Sci 2021;78:5505-26. [PMID: 34131808 DOI: 10.1007/s00018-021-03866-y] [Reference Citation Analysis]
3 Jain A, Bhardwaj V. Therapeutic resistance in pancreatic ductal adenocarcinoma: Current challenges and future opportunities. World J Gastroenterol 2021; 27(39): 6527-6550 [PMID: 34754151 DOI: 10.3748/wjg.v27.i39.6527] [Reference Citation Analysis]